Monash University update on Ivermectin trial

As indicated in our August statement on the Monash BDI news page, Dr Kylie Wagstaff has been working to establish a blinded and randomised clinical trial of Ivermectin.

The clinical trial has now commenced and has been set up as a placebo-controlled, double-blinded post-exposure prophylaxis trial.

Trial participants must be aged between 18 and 80 years of age, have been a close contact with a confirmed COVID-19 positive person within the previous 72 hours, and have tested negative to a RAT or PCR test.

If you would like more information on the eligibility and exclusion criteria or to register, please visit

Advice from the National COVID-19 clinical evidence taskforce remains in place: Ivermectin is not to be used for the prevention or treatment of COVID-19 outside clinical trials with appropriate ethical approval.

The purpose of the trial is to determine whether or not Ivermectin prevents SARS-CoV-2 infection in eligible participants after close contact with a COVID-19 positive person.

Trial results are expected late in 2022. The results of the trial will be written up and submitted to a relevant journal for peer review. We will update the progress via the BDI website.

About the Monash Biomedicine Discovery Institute at Monash University

Committed to making the discoveries that will relieve the future burden of disease, the newly established Monash Biomedicine Discovery Institute at Monash University brings together more than 120 internationally-renowned research teams. Our researchers are supported by world-class technology and infrastructure, and partner with industry, clinicians and researchers internationally to enhance lives through discovery.


Monash University
T: +61 3 9903 4840